MIG AG backs Antisense Pharma in new €8m round

MIG AG invested from its MIG funds 2, 3 and 9 with the Global Asset Fund also contributing.
The fresh capital will be used to support the company's second international clinical trial.
Additionally, it was announced that chief executive officer Dr Karl-Hermann Schlingensiepen has stepped down from his role with Dr Hubert Heinrichs taking over as acting CEO.

Company
Antisense Pharma develops antisense technology-based drugs for the targeted treatment of particularly aggressive cancers that are as yet incurable. The company's lead product, Trabedersen, is in the third phase of clinical trials and selectively inhibits the production of tumour-supporting proteins.

Trabedersen was awarded orphan drug status from the European and American authorities for high grade glioma (brain tumours) in 2002 and for the treatment of pancreatic cancer (pancreatic carcinoma) in 2009. Founded in 1998 by the Schlingensiepen family and Dr Wolfgang Brysch, the company is now located in the BioPark in Regensburg, Bavaria.

People
Dr Karl-Hermann Schlingensiepen is founder of Antisense Pharma. Michael Motschmann is the chief executive of MIG AG.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany